Posters

Intracameral moxifloxacin use in cataract surgery to prevent endophthalmitis

Poster Details

First Author: S. Cetinkaya TURKEY

Co Author(s):    Y. Cetinkaya   N. Acir   Z. Dadaci              

Abstract Details

Purpose:

To evaluate the safety and efficacy of intracameral moxifloxacin in preventing endophthalmitis after cataract surgery.

Setting:

Turkish Red Crescent Hospital, Konya, Turkey

Methods:

Sixty-five eyes of 65 patients underwent cataract surgery between January and June 2012. Some patients received intracameral moxifloxacin at the end of surgery, while others did not (controls). Pre- and postperative logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA), intraocular pressure (IOP), corneal edema, and anterior chamber (AC) status were examined.

Results:

Preoperative BCVA was approximately 20/130 in both groups. After surgery, moxifloxacin and control patients had a BCVA of 20/25 and 20/23, respectively (p = 0.160). Preoperative IOP was 14.93 ± 2.77 mmHg (range: 11–21 mmHg) in moxifloxacin patients and 15.06 ± 2.42 mmHg (range: 12–21 mmHg) in controls (P = 0.850). After surgery, IOP was not statistically different between two groups (moxifloxacin: 14.06 ± 2.31 [range: 10–19 mmHg], controls: 14.03 ± 2.36 mmHg [range: 10–19 mmHg], P = 0.960). Slight differences in corneal edema (P = 0.623) and anterior chamber cell (P = 0.726) incidences between two groups were not statistically significant.

Conclusions:

Intracameral moxifloxacin is safe and effective in preventing endophtalmitis after cataract surgery.

Financial Disclosure:

NONE